Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit
Danish Biotech Banks $40m milestone payment
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.
